Letairis
developed to target pulmonary hypertension to alleviate respiratory stress.
Strengths: 5 · 10mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Volibris
- Therapeutic class
Endothelin Receptor Antagonist
- Pharmacological class
Endothelin Receptor Antagonist
- Contraindications
pregnancy; severe hepatic impairment; hypersensitivity to components
- Minor side effects
headache; nasal congestion; flushing
- Moderate side effects
peripheral oedema; palpitations; constipation
- Dosage forms
Tablet
- Administration route
Oral use
- Patient summary
developed to target pulmonary hypertension to alleviate respiratory stress.
- Prescription status
POM
- Manufacturer
Gilead Sciences
- Onset Time
2–4 weeks
- Duration
Long-term usage
- Storage instructions
Store at room temperature.
- Drug interactions
cyclosporine
- Age restrictions
Adults.
- Pregnancy and breastfeeding
Pregnancy: Contraindicated (teratogenic). Breastfeeding: Not recommended.
Precautions and warnings
requires liver function monitoring; risk of birth defects; requires consistent contraceptive use in females
Serious side effects
liver failure — requires immediate medical attention; pulmonary oedema — requires immediate medical attention
Mechanism of action
Ambrisentan acts as a selective endothelin receptor antagonist. By blocking the binding of endothelin-1 to receptors in the pulmonary artery walls, it promotes vasodilation and helps manage elevated pressure levels.
Letairis
developed to target pulmonary hypertension to alleviate respiratory stress.
Editorial Notes
- Active ingredient(s): Ambrisentan
- Listed indication(s): Pulmonary Arterial Hypertension
Usually available as
- 30 tablets - 5 mg1511-5-mg-18008
- 30 tablets - 10 mg1511-10-mg-18011